Hengrui Medicine announces H-share offering details in Hong Kong
Jiangsu Hengrui Medicine (SSE:600276) has announced the publication of its H-share prospectus, revealing key details about its planned listing on the Hong Kong Stock Exchange. The initial price range for the H-shares is set between HKD 41.45 and HKD 44.05. The Hong Kong public offering commenced on May 15, 2025, and is expected to conclude on May 20, 2025, with the final offering price to be announced on or before May 22, 2025. The company plans to list and commence trading of its H-shares on May 23, 2025. The global offering consists of 224,519,800 H-shares, subject to adjustment options. Approximately 5.5% of the shares are earmarked for the Hong Kong public offering, with the remainder allocated for international placement. Over-allotment options are available.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime